Neoantimycin has shown potential in cancer research due to its ability to selectively target and inhibit the growth of certain cancer cells. It works by disrupting mitochondrial function, leading to the death of cancer cells while sparing normal cells. This makes it a promising candidate for developing targeted cancer therapies. Additionally, neoantimycin has been studied for its role in inducing apoptosis, or programmed cell death, in specific tumor types. Its unique mechanism of action could pave the way for novel treatments in oncology, particularly for cancers resistant to conventional therapies. Research is ongoing to explore its full therapeutic potential and optimize its efficacy.